glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell GLP-1-based therapies for diabetes, obesity
Description
Due to their preclinical testing and lack of comparison with other dual receptor agonists such as tirzepatide, further studies are needed to determine whether the effects of these unimolecular compounds are superior to those of clinically tested drugs
Epub 2024 Feb 27
Lancet 2018;391:260718.ArticlePubMed 46
88 , 89 Common reasons include gastrointestinal side effects, injection burden, high cost, and limited insurance coverage
PMID: 39535805
And the angler fish, it's probably never even heard of land, much less lizards
